Zydus Cadila receives final nod from USFDA to market Methotrexate Tablets

18 Jan 2017 Evaluate

Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Methotrexate Tablets USP, 2.5 mg. It is a chemotherapy drug used for leukemias, lymphomas, breast cancer, lung cancer, head and neck cancers and other cancers.

The drug will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×